OsamaRahmaMD

Oncology • Boston, MA

Physician

Join to view full profile

Dr. Rahma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rahma's full profile

Already have an account?

Office
450 Brookline Ave
# Dana-Far
Boston, MA 02215
Phone+1 617-632-2563

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2010 - 2014
University of HawaiiFellowship, Geriatric Medicine (Internal Medicine), 2004 - 2005
ECU Health Medical Center/East Carolina UniversityResidency, Internal Medicine, 2001 - 2004
Damascus University Faculty of MedicineClass of 1999

Certifications & Licensure

MA State Medical License 2004 - 2025
VA State Medical License 2009 - 2018
MD State Medical License 2009 - 2013
NC State Medical License 2001 - 2004

Clinical Trials

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer Start of enrollment: 2016 Oct 01
Withdrawn
Phase 2

Publications & Presentations

PubMed

68 citations
Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer.
Sara A. Väyrynen, Jinming Zhang, Chen Yuan, Juha P. Väyrynen, Andressa Dias Costa
Clinical Cancer Research. 2021-02-15
569 citations
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Austin G. Duffy, Susanna Varkey Ulahannan, Oxana Makorova-Rusher, Osama E. Rahma, Heiner Wedemeyer
Journal of Hepatology. 2017-03-01
52 citations
The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors
Osama E. Rahma, J. Michael Hamilton, Malgorzata Wojtowicz, Omar Dakheel, Sarah Bernstein
Journal of Translational Medicine. 2014-02-24

Lectures

Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: U...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): Preliminary analysis of the colorectal cancer (CRC) cohort.
2019 ASCO Annual Meeting - 6/1/2019